This article is more than 5 years old. Information may no longer be current.
Bausch + Lomb, CooperVision reaffirm their stances on UPPs
Click Here to Manage Email Alerts
In light of Johnson & Johnson Vision Care’s April announcement that the company would be discontinuing its unilateral pricing policy, Bausch + Lomb and CooperVision released statements indicating no change to their existing pricing policies.
“We are committed to our unilateral pricing policy (UPP), which is intended to encourage eye care professionals to invest the time to learn about the company’s UPP products and educate consumers, to support the UPP products as innovative offerings and to enable Bausch + Lomb to continue to provide excellent customer service related to those UPP products,” Mark McKenna, senior vice president and general manager of U.S. Vision Care for Bausch + Lomb, said in a company press release.
CooperVision has a UPP for its Clariti family of lenses that was acquired from Sauflon as well as its MyDay lenses.
CooperVision North American President Jerry Warner stated in a press release: “CooperVision has not made any changes to our policies. The company will continue to evaluate pricing and other programs to ensure that we offer high-quality, competitive products for eye care providers and patients. CooperVision ensures competitive pricing through a broad array of programs that encompass proven customer discount and loyalty opportunities and patient rebates.”
Both companies also noted their involvement in legislative activity.
“We continue to oppose any federal legislation that diminishes the pro-competitive intentions of the Fairness to Contact Lens Consumers Act through our participation in the Coalition for Patient Vision Care Safety,” McKenna said.
CooperVision said it also participates in the coalition.
“CooperVision has invested and will continue to invest in challenging policies that seek to erode the doctor-patient relationship,” Warner said. “Our leaders, consultants and lobbyists have been directly engaged in legislative activity in Washington, D.C., and multiple states, encouraging legislators to oppose bills that threaten patient safety and attempt to devalue the role of eye care professionals.”